A clinical-stage biotechnology company focused on developing therapies that target galectin proteins involved in fibrosis and cancer. Its lead drug candidate, belapectin, is being studied for the treatment of liver cirrhosis associated with nonalcoholic steatohepatitis (NASH) and portal hypertension...
1 member of Congress has disclosed 1 trade in Galent Inc (GALT), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2016-11-07 | Carlos Curbelo | sell | $1K – $15K |